Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David I Stirling

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Journal of Translational Medicine|July 21, 2007
Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanomaDavid P Mangiameli, Joseph A Blansfield, Stephan Kachala, et al.
The Journal of Surgical Research|September 4, 2009
CC-5079: a small molecule with MKP1, antiangiogenic, and antitumor activityHuan N Vu, Walter J Miller, Sarah A O'Connor, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|October 26, 2005
Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-theta activation and enhancing the DNA-binding activity of AP-1 but not NF-kappaB, OCT-1, or NF-ATFaribourz Payvandi, Lei Wu, Syedah D Naziruddin, et al.
Clinical Pharmacokinetics|April 15, 2004
Clinical pharmacokinetics of thalidomideSteve K Teo, Wayne A Colburn, William G Tracewell, et al.
Cancer Research|February 5, 2003
A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteinsJ Blake Marriott, Ian A Clarke, Anna Czajka, et al.
Blood|August 21, 2004
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myelomaNoopur Raje, Shaji Kumar, Teru Hideshima, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 22, 2003
Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugsPeter H Schafer, Anita K Gandhi, Michelle A Loveland, et al.
Microvascular Research|September 23, 2008
The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditionsLing Lu, Faribourz Payvandi, Lei Wu, et al.
Cancer Research|January 21, 2006
The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-alpha production with antitumor activityLing-Hua Zhang, Lei Wu, Heather K Raymon, et al.
Journal of Molecular Medicine (Berlin, Germany)|July 8, 2020
The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistanceJianxuan Zou, Richard J Jones, Hua Wang, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Journal of Translational Medicine|July 21, 2007
Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanomaDavid P Mangiameli, Joseph A Blansfield, Stephan Kachala, et al.
The Journal of Surgical Research|September 4, 2009
CC-5079: a small molecule with MKP1, antiangiogenic, and antitumor activityHuan N Vu, Walter J Miller, Sarah A O'Connor, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|October 26, 2005
Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-theta activation and enhancing the DNA-binding activity of AP-1 but not NF-kappaB, OCT-1, or NF-ATFaribourz Payvandi, Lei Wu, Syedah D Naziruddin, et al.
Clinical Pharmacokinetics|April 15, 2004
Clinical pharmacokinetics of thalidomideSteve K Teo, Wayne A Colburn, William G Tracewell, et al.
Cancer Research|February 5, 2003
A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteinsJ Blake Marriott, Ian A Clarke, Anna Czajka, et al.
Blood|August 21, 2004
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myelomaNoopur Raje, Shaji Kumar, Teru Hideshima, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 22, 2003
Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugsPeter H Schafer, Anita K Gandhi, Michelle A Loveland, et al.
Microvascular Research|September 23, 2008
The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditionsLing Lu, Faribourz Payvandi, Lei Wu, et al.
Cancer Research|January 21, 2006
The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-alpha production with antitumor activityLing-Hua Zhang, Lei Wu, Heather K Raymon, et al.
Journal of Molecular Medicine (Berlin, Germany)|July 8, 2020
The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistanceJianxuan Zou, Richard J Jones, Hua Wang, et al.
Pageof 3